1 results match your criteria: "Murdoch University Murdoch 6150 Australia Suxiang.Chen@murdoch.edu.au R.Veedu@murdoch.edu.au.[Affiliation]"
Inhibition of survivin by 2'--methyl phosphorothioate-modified steric-blocking antisense oligonucleotides.
RSC Adv
April 2024
Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University Murdoch 6150 Australia
Article Synopsis
- Chemically modified antisense oligonucleotides (ASOs) have been proven effective in treating various diseases, with ten approved ASO drugs currently on the market, mainly for conditions other than cancer.
- Researchers have developed steric-blocking ASOs that specifically target a known oncogene, initially screening seven candidates in HepG2 cells and identifying ASO-2 and ASO-7 as the most effective in reducing mRNA levels.
- Further testing demonstrated that ASO-7 not only inhibited mRNA expression in a dose-dependent manner but also significantly reduced survivin protein levels, suggesting its potential as a therapeutic BIRC5 inhibitor.